Moderna Inc MRNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MRNA is a good fit for your portfolio.
News
-
Moderna, CureVac, other vaccine stocks jump as new human bird-flu cases reported in U.S., Australia
-
Trending: Moderna's Proposed RSV Vaccine Faces Delayed FDA Review
-
Moderna says FDA will not complete review of RSV vaccine by May 12 deadline
-
Moderna: FDA Extends RSV Vaccine Review, But No Issues Flagged
-
Moderna's stock surges after better-than-expected quarterly results
-
Moderna's stock jumps 6% as its cancer vaccine could treat more than just melanoma
-
Health Care Stocks Steady, Moderna Climbs — Health Care Roundup
-
Blackstone to Fund Moderna's Flu Research With up to $750 Million
Trading Information
- Previous Close Price
- €153.76
- Day Range
- €153.78–154.76
- 52-Week Range
- €64.46–154.76
- Bid/Ask
- €153.52 / €154.06
- Market Cap
- €58.93 Bil
- Volume/Avg
- 0 / 250
Key Statistics
- Price/Earnings (Normalized)
- 56.78
- Price/Sales
- 11.86
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 1.00%
Company Profile
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 5,600
- Website
- https://www.modernatx.com
Competitors
Valuation
Metric
|
MRNA
|
JNJ
|
BNTX
|
---|---|---|---|
Price/Earnings (Normalized) | 56.78 | 14.75 | 32.26 |
Price/Book Value | 4.70 | 5.30 | 1.13 |
Price/Sales | 11.86 | 4.33 | 8.34 |
Price/Cash Flow | — | 16.67 | — |
Price/Earnings
MRNA
JNJ
BNTX
Financial Strength
Metric
|
MRNA
|
JNJ
|
BNTX
|
---|---|---|---|
Quick Ratio | 3.21 | 0.84 | 10.95 |
Current Ratio | 3.42 | 1.17 | 11.38 |
Interest Coverage | −113.82 | 23.57 | — |
Quick Ratio
MRNA
JNJ
BNTX
Profitability
Metric
|
MRNA
|
JNJ
|
BNTX
|
---|---|---|---|
Return on Assets (Normalized) | −20.12% | 12.64% | −0.14% |
Return on Equity (Normalized) | −26.85% | 31.72% | −0.15% |
Return on Invested Capital (Normalized) | −26.68% | 20.11% | −2.21% |
Return on Assets
MRNA
JNJ
BNTX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tktdnvzs | Dkcx | $605.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nrbmcnsv | Sfzvt | $116.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ybnypdcn | Yznmf | $108.5 Bil | |
MRNA
| Moderna Inc | Dzvsmfwf | Rygq | $62.9 Bil | |
BNTX
| BioNTech SE ADR | Jgwwclfql | Zqcq | $23.4 Bil | |
ARGX
| argenx SE ADR | Qvrznrwz | Lfj | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qvvmprwd | Zswwsvk | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pkfnhkw | Hcthxkc | $14.3 Bil | |
INCY
| Incyte Corp | Znprdhpc | Pjyxym | $12.9 Bil | |
UTHR
| United Therapeutics Corp | Gjrsqgr | Hpstq | $12.1 Bil |